Citizens Reaffirms Buy Rating on KURA with $24 Target
Citizens continues to see upside in KURA, maintaining a buy rating and setting a $24 price target.
Key Points
- On June 15, 2026, Citizens reiterated its buy rating on KURA, setting a price target of $24.
- KURA shares are trading around $9.05, showing potential for significant upside according to analysts.
- Recent insider buying and institutional activity indicate growing interest in KURA stock.
On June 15, 2026, Citizens reiterated its buy rating for KURA, setting a price target of $24. The stock is currently trading at about $9.05, suggesting potential upside if the target is reached.
Other Institutional Activity in KURA
Several institutional investors have recently adjusted their positions in KURA. BlackRock, Inc. increased its stake by 626,738 shares, bringing its total to 9,637,531 shares valued at approximately $78.3 million. Suvretta Capital Management, LLC maintained its holdings at 8,575,422 shares worth about $69.7 million. BVF Inc/IL reduced its position by 171,393 shares, holding 8,445,769 shares valued at $68.7 million. State Street Corp decreased its stake by 419,199 shares, now holding 4,511,891 shares worth $36.7 million. Meanwhile, Vanguard Capital Management LLC initiated a new position with 3,785,685 shares valued at $30.8 million.
KURA Stock Snapshot
KURA shares are trading near $9.05. The stock has caught the attention of analysts and investors alike, with several institutions adjusting their holdings and analysts maintaining optimistic price targets.
Insider Buying and Selling at Kura Oncology, Inc.
In a notable show of confidence, several insiders purchased shares on June 4, 2026. Thomas Malley, Faheem Hasnain, Helen Louise Collins, Carol Schafer, Michael Vasconcellos, and Mary Szela each bought 35,000 shares. These transactions were not part of any pre-planned trading plan.
Analysts Set New Price Targets
On June 15, 2026, Citizens reiterated its buy rating for KURA with a $24 price target. Other analysts have also shown optimism. Lake Street initiated coverage with a buy rating and a $23 target on April 14, 2026. Mizuho maintained its buy rating on March 24, 2026, with a $25 target. UBS and Wedbush also maintained buy ratings with targets of $15 and $36, respectively.
About KURA
KURA is a biopharmaceutical company focused on developing innovative therapies for cancer treatment. The company is committed to advancing its pipeline of targeted drugs to improve the lives of patients with serious diseases.
Bottom Line
Citizens' reiterated buy rating and $24 price target for KURA underscore the potential seen in the company's future performance. The stock's current price and recent insider buying suggest strong interest and confidence in KURA's prospects. As always, these analyst ratings are based on past data and expectations, and investors should consider the full range of information available.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.